Evolent (EVH) Q1 2026 Earnings Call Transcript

Evolent Health reported Q1 revenue of $496 million, up 9% sequentially excluding ECP, with adjusted EBITDA of $22 million and MER improving 150 bps to 93%. Management reaffirmed full-year 2026 guidance of $2.4 billion-$2.6 billion revenue and $110 million-$140 million adjusted EBITDA, while highlighting two major new contracts, including an imaging deal covering 4.5 million lives and a national payer expansion expected to add over $200 million in annual revenue. Near-term headwinds remain around exchange membership decline and elevated Specialty T&S servicing costs, but the company said these pressures should normalize by late Q2.

Analysis

EVH is transitioning from a pure utilization-management story into a platform/consolidation story, and that changes the competitive setup. The reverse cross-sell into imaging is the key tell: once a payer standardizes on the operating layer, the marginal cost of adding adjacent specialties collapses, which should favor the few vendors with enough scale, data, and implementation muscle to bundle across categories. That is a medium-term threat to niche UM vendors and a subtle positive for large managed-care clients that can force price concessions by reducing vendor count.

The bigger second-order effect is on quality of earnings. Near-term revenue is being pulled around by exchange membership churn and launch timing, but the contracts coming on now are structurally more valuable if management can keep auto-approval rates rising without impairing clinical outcomes. If the imaging models really sustain high-teens to ~30% auto-approval gains, the operating leverage shows up with a lag: lower servicing cost, faster turnaround, and eventually better retention at renewal, even if reported MER remains noisy through Q3. The market may be underappreciating that the automation initiative is not just cost takeout; it is a capacity unlock that lets EVH absorb more lives without linear headcount growth.

The main risk window is the next 6-10 weeks, not the next year. Q2 visibility on disenrollment is the swing factor: if the exchange decline comes in worse than the assumed 40%, both revenue and servicing costs can disappoint simultaneously before contractual protections normalize later. Conversely, if the decline is less severe, the stock likely re-rates quickly because the current setup leaves little room for a clean second-half beat once the Highmark ramp and large expansion contract start landing.

Key Decisions for Investors

• Long EVH vs. short a higher-multiple healthcare services peer basket for the next 2-3 months: the setup favors EVH if Q2 exchange visibility improves and launch risk fades; downside is limited by reiterated guidance, upside is a de-risking re-rate.
• Buy EVH shares on weakness only after the market digests Q2 disenrollment data (late Q2 timing): better asymmetry than chasing after the contract announcements, because the stock is still exposed to one more quarter of servicing-cost noise.
• Sell out-of-the-money EVH puts 1-2 quarters out if options liquidity allows: management has effectively anchored full-year EBITDA, and implied downside should overstate near-term fundamental risk once the exchange overhang clears.
• Pair long EVH / short UNH or a managed-care services proxy on a 3-6 month horizon: EVH has more operating leverage to AI-driven workflow gains, while the short leg helps hedge broader payer multiple compression.
• If already long EVH, trim into any Q2 rally and re-add after the Highmark launch is fully reflected in reported numbers: the cleanest upside likely comes from confirmation, not anticipation.